FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029041840> ?p ?o ?g. }

• W2029041840 endingPage "2151" @default.
• W2029041840 startingPage "2146" @default.
• W2029041840 abstract "BACKGROUND. Intracranial meningiomas are common, they frequently recur after surgery or radiotherapy, and there are limited data regarding the treatment of intracranial meningiomas with chemotherapy. A phase 2 study was designed to estimate the 6-month progression-free survival of patients with recurrent, treatment-refractory, World Health Organization grade 1 meningiomas who were treated with interferon-α. METHODS. Thirty-five patients with recurrent meningiomas ranging in age from 36 years to 88 years (median age, 61 years) were treated according to a prospective phase 2 study. All patients had received prior surgery, radiotherapy, (involved-field radiotherapy in 35 patients andstereotactic radiotherapy in 22 patients), and chemotherapy (hydroxyurea in 19 patients and other in 17 patients). On radiographic documentation of progressive disease, interferon-α (at a dose of 10 million U/m2 administered subcutaneously every other day) was initiated. A complete blood count and chemistry panel was obtained before every cycle, and cranial magnetic resonance images were obtained every 3 months. RESULTS. The most common grade 3 and 4 toxicities were fatigue (6 patients; 17%), anemia (3 patients; 8.6%), and leukopenia (3 patients; 8.6%) (toxicities were graded according to the National Cancer Institute's Common Toxicity Criteria [version 3.0]). Three patients went off study because of toxicity, and 7 patients required a dose reduction. There were no treatment-related deaths or delays in therapy reported. All patients were assessable for response. No patient demonstrated a neuroradiographic complete or partial response. Twenty-six patients demonstrated stable disease after the first 3 cycles of interferon-α, and 9 patients had progressive disease. The progression-free survival rate was 54% at 6 months and 31% at 12 months. The median time to tumor progression was 7 months (range, 2-24 months). The median survival was 8 months (range, 3-28 months). CONCLUSIONS. Treatment with interferon-α for recurrent meningiomas was found to be tolerated moderately well and was modestly effective. Cancer 2008. © 2008 American Cancer Society." @default.
• W2029041840 created "2016-06-24" @default.
• W2029041840 creator A5028023803 @default.
• W2029041840 creator A5070567202 @default.
• W2029041840 date "2008-10-15" @default.
• W2029041840 modified "2023-10-15" @default.
• W2029041840 title "Interferon-α for recurrent World Health Organization grade 1 intracranial meningiomas" @default.
• W2029041840 cites W1588978149 @default.
• W2029041840 cites W1765121683 @default.
• W2029041840 cites W1828940258 @default.
• W2029041840 cites W1959628099 @default.
• W2029041840 cites W1963483230 @default.
• W2029041840 cites W1963673993 @default.
• W2029041840 cites W1970539961 @default.
• W2029041840 cites W1973762438 @default.
• W2029041840 cites W1983716488 @default.
• W2029041840 cites W1988952766 @default.
• W2029041840 cites W1997207651 @default.
• W2029041840 cites W1998033850 @default.
• W2029041840 cites W2013187784 @default.
• W2029041840 cites W2014851190 @default.
• W2029041840 cites W2017400629 @default.
• W2029041840 cites W2034972449 @default.
• W2029041840 cites W2038017076 @default.
• W2029041840 cites W2049571882 @default.
• W2029041840 cites W2060724712 @default.
• W2029041840 cites W2070946313 @default.
• W2029041840 cites W2080027808 @default.
• W2029041840 cites W2095900366 @default.
• W2029041840 cites W2102047778 @default.
• W2029041840 cites W2103580195 @default.
• W2029041840 cites W2118302917 @default.
• W2029041840 cites W2140652292 @default.
• W2029041840 cites W2146404641 @default.
• W2029041840 cites W2148017192 @default.
• W2029041840 cites W2154024950 @default.
• W2029041840 cites W2334694951 @default.
• W2029041840 cites W3140666778 @default.
• W2029041840 cites W4376595513 @default.
• W2029041840 doi "https://doi.org/10.1002/cncr.23803" @default.
• W2029041840 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18756531" @default.
• W2029041840 hasPublicationYear "2008" @default.
• W2029041840 type Work @default.
• W2029041840 sameAs 2029041840 @default.
• W2029041840 citedByCount "102" @default.
• W2029041840 countsByYear W20290418402012 @default.
• W2029041840 countsByYear W20290418402013 @default.
• W2029041840 countsByYear W20290418402014 @default.
• W2029041840 countsByYear W20290418402015 @default.
• W2029041840 countsByYear W20290418402016 @default.
• W2029041840 countsByYear W20290418402017 @default.
• W2029041840 countsByYear W20290418402018 @default.
• W2029041840 countsByYear W20290418402019 @default.
• W2029041840 countsByYear W20290418402020 @default.
• W2029041840 countsByYear W20290418402021 @default.
• W2029041840 countsByYear W20290418402022 @default.
• W2029041840 countsByYear W20290418402023 @default.
• W2029041840 crossrefType "journal-article" @default.
• W2029041840 hasAuthorship W2029041840A5028023803 @default.
• W2029041840 hasAuthorship W2029041840A5070567202 @default.
• W2029041840 hasBestOaLocation W20290418401 @default.
• W2029041840 hasConcept C126322002 @default.
• W2029041840 hasConcept C141071460 @default.
• W2029041840 hasConcept C188816634 @default.
• W2029041840 hasConcept C2776694085 @default.
• W2029041840 hasConcept C2778248108 @default.
• W2029041840 hasConcept C2778822529 @default.
• W2029041840 hasConcept C2780873365 @default.
• W2029041840 hasConcept C509974204 @default.
• W2029041840 hasConcept C71924100 @default.
• W2029041840 hasConceptScore W2029041840C126322002 @default.
• W2029041840 hasConceptScore W2029041840C141071460 @default.
• W2029041840 hasConceptScore W2029041840C188816634 @default.
• W2029041840 hasConceptScore W2029041840C2776694085 @default.
• W2029041840 hasConceptScore W2029041840C2778248108 @default.
• W2029041840 hasConceptScore W2029041840C2778822529 @default.
• W2029041840 hasConceptScore W2029041840C2780873365 @default.
• W2029041840 hasConceptScore W2029041840C509974204 @default.
• W2029041840 hasConceptScore W2029041840C71924100 @default.
• W2029041840 hasIssue "8" @default.
• W2029041840 hasLocation W20290418401 @default.
• W2029041840 hasLocation W20290418402 @default.
• W2029041840 hasOpenAccess W2029041840 @default.
• W2029041840 hasPrimaryLocation W20290418401 @default.
• W2029041840 hasRelatedWork W1448091729 @default.
• W2029041840 hasRelatedWork W1511187821 @default.
• W2029041840 hasRelatedWork W2357273538 @default.
• W2029041840 hasRelatedWork W2361544313 @default.
• W2029041840 hasRelatedWork W2367148332 @default.
• W2029041840 hasRelatedWork W2387267110 @default.
• W2029041840 hasRelatedWork W2392383546 @default.
• W2029041840 hasRelatedWork W2419081241 @default.
• W2029041840 hasRelatedWork W2607777675 @default.
• W2029041840 hasRelatedWork W3149210031 @default.
• W2029041840 hasVolume "113" @default.
• W2029041840 isParatext "false" @default.
• W2029041840 isRetracted "false" @default.
• W2029041840 magId "2029041840" @default.

• next